Naltrexone for Heavy Drinking in Young Adults

This study has been completed.
Sponsor:
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT00568958
First received: December 4, 2007
Last updated: July 22, 2014
Last verified: July 2014
Results First Received: March 4, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Conditions: Alcohol Consumption
Alcoholic Intoxication
Alcoholism
Alcohol-induced Disorders
Interventions: Behavioral: BASICS counseling
Drug: naltrexone
Drug: placebo naltrexone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment occurred primarily through Facebook advertisements and fliers. Following initial screening by phone or online surveys, individuals were invited for intake conducted by the research assistant at an outpatient university research clinic where written informed consent was obtained.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Naltrexone

Active naltrexone (25 mg daily +25 targeted)+ BASICS counseling

BASICS counseling: Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.

naltrexone: Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.

Placebo Naltrexone

Placebo Naltrexone (targeted + daily) + BASICS Counseling

BASICS counseling: Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.

placebo naltrexone: Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.


Participant Flow for 2 periods

Period 1:   Allocation
    Naltrexone   Placebo Naltrexone
STARTED   70   70 
COMPLETED   61   67 
NOT COMPLETED   9   3 
Withdrawal by Subject                7                3 
Physician Decision                2                0 

Period 2:   Follow-Up
    Naltrexone   Placebo Naltrexone
STARTED   61   67 
COMPLETED   53   63 
NOT COMPLETED   8   4 
Withdrawal by Subject                6                3 
Physician Decision                1                1 
Family Emergency                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Naltrexone

Active naltrexone (25 mg daily +25 targeted)+ BASICS counseling

BASICS counseling: Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.

naltrexone: Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.

Placebo Naltrexone

Placebo Naltrexone (targeted + daily) + BASICS Counseling

BASICS counseling: Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.

placebo naltrexone: Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.

Total Total of all reporting groups

Baseline Measures
   Naltrexone   Placebo Naltrexone   Total 
Overall Participants Analyzed 
[Units: Participants]
 61   67   128 
Age, Customized 
[Units: Participants]
     
18-25 year olds   61   67   128 
Gender 
[Units: Participants]
     
Female   18   22   40 
Male   43   45   88 
Race/Ethnicity, Customized 
[Units: Participants]
     
Caucasian   49   50   99 
Non-Caucasian   12   17   29 
Alcohol Use Diagnosis 
[Units: Participants]
     
No Diagnosis   16   11   27 
Alcohol Abuse   11   14   25 
Alcohol Dependence   34   42   76 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Frequency of Heavy Episodic Drinking   [ Time Frame: Baseline ]

2.  Primary:   Frequency of Heavy Episodic Drinking   [ Time Frame: eight weeks ]

3.  Primary:   Percent Days Abstinent From Drinking   [ Time Frame: Baseline ]

4.  Primary:   Percent Days Abstinent From Drinking   [ Time Frame: 8 Weeks ]

5.  Secondary:   Number of Drinks Per Drinking Day   [ Time Frame: Baseline ]

6.  Secondary:   Number of Drinks Per Drinking Day   [ Time Frame: 8 Weeks ]

7.  Secondary:   Percentage of Drinking to an Estimated Blood Alcohol Concentration (BAC) of .08 or Higher   [ Time Frame: 8 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Stephanie S. O'Malley
Organization: Yale University School of Medicine
phone: 203-974-7590
e-mail: stephanie.omalley@yale.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00568958     History of Changes
Other Study ID Numbers: NIAAA_OMALLEY-AA016621
R01AA016621 ( US NIH Grant/Contract Award Number )
NIH grant AA016621-01
Study First Received: December 4, 2007
Results First Received: March 4, 2014
Last Updated: July 22, 2014